January 5, 2017 / 1:51 PM / in 7 months

BRIEF-OncoMed announces year-end cash balance and 2017 outlook

1 Min Read

Jan 5 (Reuters) - Oncomed Pharmaceuticals Inc

* OncoMed announces year-end cash balance and 2017 outlook

* Expects 2017 operating cash burn to be less than $100 million, before considering potential milestones/opt-ins

* "Phase 2 clinical trial results for demcizumab and tarextumab are anticipated in first half of year"

* "Oncomed could receive more than $170 million in total 2017 partner opt-in payments"

* Expects to file an IND in first half of 2017 for Oncomed's wholly owned GITRL-FC (OMP-336B11) trimer program Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below